Andrew J Li1, R Geoffrey Elmore, Ida Yii-der Chen, Beth Y Karlan. 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA. Andrew.Li@cshs.org
Abstract
OBJECTIVE: Recent data suggest patients with epithelial ovarian cancers on statin therapy have improved survival. We have hypothesized that statins influence ovarian cancer outcome through alteration of lipoprotein profiles, and sought to determine correlations between lipoprotein levels and survival in women with advanced stage disease. METHODS: After IRB approval, we identified patients with stage IIIC/IV epithelial ovarian cancer with banked prediagnostic fasting serum. Serum was assayed for levels of total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG). LDL was calculated by subtraction of TG/5 and HDL from TC. Data were examined using Fisher's exact, Kaplan-Meier, and Cox regression analyses. RESULTS: One hundred thirty-two patients were studied. Twenty-six percent of patients had elevated LDL; 18% had elevated TC; 32% had elevated TG; and 48% had elevated HDL. No univariate associations were identified between elevated TC, HDL, TG, LDL and age, stage IV disease, high grade, or optimal cytoreduction. Median progression-free survival for patients with normal LDL levels was 27 months, compared to 12 months for patients with elevated LDL (p=0.0004). Overall disease-specific survival was longer for patients with normal LDL levels (59 months) compared to those with elevated LDL (51 months, p=0.04). Multivariate analysis indicated that LDL retained significance as an independent predictor of survival, after controlling for age, stage, grade, and suboptimal cytoreduction (p=0.003). CONCLUSIONS: These data suggest LDL is a significant predictor of clinical outcome, and warrant the further study of lipoproteins and statins on epithelial ovarian cancer biology.
OBJECTIVE: Recent data suggest patients with epithelial ovarian cancers on statin therapy have improved survival. We have hypothesized that statins influence ovarian cancer outcome through alteration of lipoprotein profiles, and sought to determine correlations between lipoprotein levels and survival in women with advanced stage disease. METHODS: After IRB approval, we identified patients with stage IIIC/IV epithelial ovarian cancer with banked prediagnostic fasting serum. Serum was assayed for levels of total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG). LDL was calculated by subtraction of TG/5 and HDL from TC. Data were examined using Fisher's exact, Kaplan-Meier, and Cox regression analyses. RESULTS: One hundred thirty-two patients were studied. Twenty-six percent of patients had elevated LDL; 18% had elevated TC; 32% had elevated TG; and 48% had elevated HDL. No univariate associations were identified between elevated TC, HDL, TG, LDL and age, stage IV disease, high grade, or optimal cytoreduction. Median progression-free survival for patients with normal LDL levels was 27 months, compared to 12 months for patients with elevated LDL (p=0.0004). Overall disease-specific survival was longer for patients with normal LDL levels (59 months) compared to those with elevated LDL (51 months, p=0.04). Multivariate analysis indicated that LDL retained significance as an independent predictor of survival, after controlling for age, stage, grade, and suboptimal cytoreduction (p=0.003). CONCLUSIONS: These data suggest LDL is a significant predictor of clinical outcome, and warrant the further study of lipoproteins and statins on epithelial ovarian cancer biology.
Authors: Marilyn L Kwan; Laurel A Habel; E Dawn Flick; Charles P Quesenberry; Bette Caan Journal: Breast Cancer Res Treat Date: 2007-08-03 Impact factor: 4.872
Authors: Elizabeth A Platz; Michael F Leitzmann; Kala Visvanathan; Eric B Rimm; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2006-12-20 Impact factor: 13.506
Authors: Godwin O Ifere; Erika Barr; Anita Equan; Kereen Gordon; Udai P Singh; Jaideep Chaudhary; Joseph U Igietseme; Godwin A Ananaba Journal: Cancer Detect Prev Date: 2009-01-30
Authors: Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner Journal: Proc Natl Acad Sci U S A Date: 2010-11-01 Impact factor: 11.205
Authors: Sisi He; Liqian Ma; Amy E Baek; Anna Vardanyan; Varsha Vembar; Joy J Chen; Adam T Nelson; Joanna E Burdette; Erik R Nelson Journal: Endocr Relat Cancer Date: 2019-07 Impact factor: 5.678
Authors: Ellen L Hedditch; Bo Gao; Amanda J Russell; Yi Lu; Catherine Emmanuel; Jonathan Beesley; Sharon E Johnatty; Xiaoqing Chen; Paul Harnett; Joshy George; Rebekka T Williams; Claudia Flemming; Diether Lambrechts; Evelyn Despierre; Sandrina Lambrechts; Ignace Vergote; Beth Karlan; Jenny Lester; Sandra Orsulic; Christine Walsh; Peter Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Keitaro Matsuo; Satoyo Hosono; Toru Nakanishi; Yasushi Yatabe; Tanja Pejovic; Yukie Bean; Florian Heitz; Philipp Harter; Andreas du Bois; Ira Schwaab; Estrid Hogdall; Susan K Kjaer; Allan Jensen; Claus Hogdall; Lene Lundvall; Svend Aage Engelholm; Bob Brown; James Flanagan; Michelle D Metcalf; Nadeem Siddiqui; Thomas Sellers; Brooke Fridley; Julie Cunningham; Joellen Schildkraut; Ed Iversen; Rachel P Weber; Andrew Berchuck; Ellen Goode; David D Bowtell; Georgia Chenevix-Trench; Anna deFazio; Murray D Norris; Stuart MacGregor; Michelle Haber; Michelle J Henderson Journal: J Natl Cancer Inst Date: 2014-06-23 Impact factor: 13.506
Authors: Mohammed Habis; Kristen Wroblewski; Michael Bradaric; Nadia Ismail; S Diane Yamada; Lacey Litchfield; Ernst Lengyel; Iris L Romero Journal: PLoS One Date: 2014-08-13 Impact factor: 3.240